Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
A Phase I Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-001, an anti-CD74 Antibody Drug Conjugate, in Patients with Advanced B-Cell Malignancies
Omega 3 Fatty Acids in Colorectal Cancer CRC Prevention in Patients with Lynch Syndrome COLYNE
Study Type: Prevention
Phase: Feasibility/Pilot
NCTID: NCT03831698
Principal Investigator:
Anwaar Saeed
NCI-COG PEDIATRIC MATCH MOLECULAR ANALYSIS FOR THERAPY CHOICE- PHASE 2 SUBPROTOCOL OF LOXO-101 LAROTRECTINIB IN PATIENTS WITH TUMORS HARBORING ACTIONABLE NTRK FUSIONS
Study Type: Treatment
Phase: II
NCTID: NCT03213704
Principal Investigator:
Kevin Ginn
Assessing the Utility of Ultrasound Compared to Cross-Sectional Imaging in the Follow-up of Patients with Renal Cell Carcinoma
A Phase I Study of DS-3032B in Combination with Quizartinib in Subjects with FLT3-ITD Mutant Acute Myeloid Leukemia That are Relapsed/Refractory, or Newly Diagnosed and Unfit for Intensive Chemotherapy
An Open-Label Feasibility Study to Assess the Safety and Pharmacokinetics of Enasidenib in Pediatric Patients with Relapsed/Refractory Acute Myeloid Leukemia R/R-AML with an Isocitrate Dehydrogenase-2 IDH2 Mutation
Study Type: Treatment
Phase: Feasibility/Pilot
NCTID: NCT04203316
Principal Investigator:
Kevin Ginn
Phase I Multicenter, Open Label, Dose-Escalation Study to Determine The Maximum Tolerated Dose For Trichostatin A in Subjects With Relapsed or Refractory Hematologic Malignancies
Study Type: Treatment
Phase: I
NCTID: NCT03838926
Principal Investigator:
Anusha Vallurupalli
A Phase III, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelphia Chromosome?Positive Acute Lymphoblastic Leukemia Ph+ ALL
Pilot Study of Effects of Bazedoxifene plus Conjugated Estrogen on Imaging and Blood Biomarkers In Women with Menopausal Symptoms at Increased Risk for Breast Cancer
Study Type: Prevention
Phase: Feasibility/Pilot
NCTID: NCT04821375
Principal Investigator:
Carol Fabian
A Phase I/II Open-Label Trial of CPI-613� devimistat plus Hydroxychloroquine to Evaluate Maximally Tolerated Dose MTD, Safety and Efficacy in Patients with Relapsed or Refractory Clear Cell Sarcoma CCS
Study Type: Treatment
Phase: I/II
NCTID: NCT04593758
Principal Investigator:
Benjamin Powers